
## Trustees’ Annual Report 2025 

UK Acute Oncology Society (UKAOS) 

## **Charity registration number:** 1199351 

**Legal form:** Charitable Incorporated Organisation (CIO) **Reporting period:** [insert start date] to [insert end date] **Gross income:** Less than £25,000 

**Principal office:** UKAOS Secretariat, c/o Media1 Productions Ltd, Clarence Mill, Clarence Road, Bollington, Macclesfield SK10 5JZ 

## Reference and administrative details 

## **Trustees who served during the reporting period:** 

- Ernest Marshall Chair 

- Joanne Upton Trustee 

- Donna Munro Trustee 

- Philippa Jacqueline Jones Trustee 

- Dr Hilary Williams Trustee 

- Dr Caroline Wilson Trustee 

## Structure, governance and management 

UKAOS is a Charitable Incorporated Organisation governed by its constitution dated 16 June 2022 and updated on 18 January 2025. The Board of Trustees is responsible for the charity’s strategic direction, financial stewardship, legal compliance and oversight of risk. 

## Trustee appointment, induction and organisation 

Trustees are appointed in accordance with the constitution, having regard to the skills, experience and diversity of perspective required by the Board. New trustees receive appropriate induction on the charity’s purposes, governing document, trustee duties, finances and current priorities. 

## How the charity is managed 

- Board of Trustees: The governing body responsible for the overall strategic direction, financial oversight, and legal compliance of the charity. 

- Operational Steering Group: Oversight of Operational delivery of the work plan and strategy 

1 




- Programme Management Group: Responsibility for cross cutting themes and governance policy development. 

- Sub-groups with defined scope and terms of reference. 

## Objectives and activities 

## Charitable purposes 

- For the public benefit to advance the education of all healthcare professionals involved in treating or supporting patients in the field of acute oncology 

- In furtherance of the object above, to promote research for the public benefit in all aspects of that subject and to publish the useful results 

- The relief of sickness and preservation of health, from cancer. 

- To assist in the treatment and care of persons suffering from cancer, or in need of rehabilitation, by the provision of education for healthcare professionals 

- To promote the wellbeing of people suffering from acute effects of cancer and/or anti-cancer treatment and support the development of acute oncology services 

## Public benefit 

The trustees have had due regard to the Charity Commission’s guidance on public benefit when planning and delivering the charity’s work. 

UKAOS advances education for healthcare professionals involved in acute oncology, promotes research and dissemination of useful findings, and supports improvements in the treatment, care and wellbeing of people affected by cancer and the acute effects of cancer treatment. 

During the year, the charity delivered public benefit through: 

- **Education:** conferences, online learning and professional events designed to improve the quality and safety of urgent cancer care. 

- **Service improvement:** development and publication of practical pathways, reviews and guidance for acute oncology services. 

- **Research, data and policy:** collaboration with national partners to strengthen evidence, data quality and the voice of acute oncology in national cancer policy. 

## Achievements and performance 

The charity’s principal achievements during the year are summarised under six strategic themes. 

2 




1. **Publications and guidance.** Published the first five-year UKAOS strategy; launched a four-nation review of 24/7 systemic anti-cancer therapy helplines; published initial Same Day Emergency Care pathways for unexpected pulmonary embolism, metastatic spinal cord compression and low-risk febrile neutropenia; and progressed reviews of malignancy of unknown origin services and acute oncology in emergency departments. 

2. **Education.** Delivered the UKAOS annual conference and established the online Learning Hour programme, alongside contributions to national oncology and systemic anti-cancer therapy events. 

3. **Urgent cancer care data.** Continued work to improve reporting through the Cancer Outcomes and Services Dataset and CancerStats2, and secured a national partnership with Macmillan Cancer Support and the National Disease Registration Service to investigate urgent-care use among people with lung cancer receiving systemic anti-cancer therapy. 

4. **Governance and policy.** Completed a governance review, established an Operational Steering Group and continued to develop policies and procedures to support effective oversight. 

5. **Income generation.** Explored fundraising opportunities to strengthen the charity’s education and service-improvement work. 

6. **National policy.** Supported the inclusion of a commitment to develop acute and supportive oncology quality standards within national cancer policy. 

## Financial review 

The charity’s gross income for the reporting period was less than £25,000. Full details of receipts, payments, assets and liabilities are set out in the annual accounts approved by the trustees. 

**Reserves:** The charity did not have a formally approved reserves policy at the reporting date. The trustees will develop and approve an appropriate policy during 2026, taking account of planned commitments, financial risks and the need for operational continuity. 

**Going concern:** Having reviewed available funds and anticipated commitments, the trustees consider that the charity has adequate resources to continue its activities for the foreseeable future, subject to confirmation when approving the accounts. 

3 




**Debts and custodian funds:** “The charity had no material debts and held no funds as custodian trustee at the year end.”] 

## Risk management and trustee 

## responsibilities 

The trustees regularly consider the principal risks facing the charity and take proportionate steps to manage them. These include financial sustainability, governance capacity, data protection, reputation and delivery of activities through partners or volunteers. 

The trustees are responsible for maintaining proper accounting records, safeguarding the charity’s assets, preparing annual accounts and a trustees’ annual report, and ensuring that the charity acts in accordance with its constitution and applicable law. 

**Serious incidents:** No  serious incidents requiring a report to the Charity Commission were identified 

## Plans for the next reporting period 

- Continue delivery of accessible education for acute oncology professionals. 

- Complete and disseminate further service reviews, pathways and guidance. 

- Strengthen partnerships supporting urgent cancer care data and research. 

- Embed the revised governance framework and complete the next phase of policy development. 

- Approve a proportionate reserves policy and pursue sustainable income opportunities. 

## Approval and declaration 

This report was approved by the Board of Trustees on [insert date] and signed on its behalf by: 

## **Ernest Marshall, Chair** 

4 




Signature: ____ __________________________ Date: ___________02/09/2026___________________ 

5 



## **2025** 

|**⚖**<br>**CHARITY COMMISSION**<br>**FOR ENGLAND AND WALES**||CharityName|CharityName|
|---|---|---|---|
|||**UK Acute Oncology Society (UKAOS)**||
|||||
|||**For the period**<br>**from**|Period start date<br>1-Jan-25|



**Section A Receipts and payments** 

**Unrestricted Restricted funds funds to the nearest £ to the nearest £** 

## **A1 Receipts** 

|**A1 Receipts**|||
|---|---|---|
|Sponsorships and grants|25,000||
||||
||||
||||
||||
|**_Sub total (Gross income for_**<br>**_AR)_**|**25,000**|**-**|
||||
|Funds received in error|0||
||||
|**_Sub total_**|**0**|**-**|
||||
|**_Total receipts_**|**25,000**||
||||
|**A3 Payments**|||
|Bank charges|240||
|Website expenses|1473||
|Secretariat|6,708||
|Accountancy|924||
|Repayment for funds received in<br>error|0||
||||
||||
||||
|**_Sub total_**|**9,345**|**-**|
||||
||||
||||





|**_Sub total_**||**-**|
|---|---|---|
||||
|**_Total payments_**|**9,345**|**-**|
||||
|**_Net of receipts/(payments)_**|**15,655**|**-**|
|A5 Transfers between funds|4,755||
|**_A6 Cash funds last year end_**|**20,410**|**-**|



## **Section B Statement of assets and liabilities at the end of the period** 

**Categories Details B1 Cash funds** Bank 

|**B2**<br>**Other monetary assets**<br>**B3**<br>**Investment assets**|**Details**|
|---|---|
|||
|||
|||
|||
|||
|||
||**Details**|
|||
|||
|||
|||
|||





## **Details** 

**B4** 

**Assets retained for the charity's own use** 

## **Details** 

**B5** 

Signed by one or two trustees on behalf of all the trustees 

**Liabilities** 

Signa 

CCXX R2 accounts (SS) 



No (if any) 1199351 **Receipts and payments accounts** Period end date **To** 31-Dec-25 

|**Endowment**<br>**Total funds**<br>**funds**<br>**to the nearest £**<br>**to the nearest £**|**Endowment**<br>**Total funds**<br>**funds**<br>**to the nearest £**<br>**to the nearest £**||**Last year**<br>**to the nearest £**|
|---|---|---|---|
|||||
|||||
||25,000||14,000|
||-|||
||-|||
||-|||
||-|||
|**-**|**25,000**||**14,000**|
|||||
||0||4,800|
|||||
|**-**|**0**||**4,800**|
|||||
||**25,000**||**18,800**|
|||||
|||||
||240||265|
||1473||848|
||6708||21,306|
||924||900|
||||10,800|
|||||
|||||
|||||
|**-**|**9,345**||**34,119**|
|||||
|||||
||-|||





|**-**|**-**|**-**|
|---|---|---|
||||
|**-**|**9,345**|**34,119**|
||||
|**-**|**15,655**|**-15,319**|
||4,755|20,074|
|**-**|**20,410**|**4,755**|



**Unrestricted Restricted funds funds to nearest £ to nearest £** 20,410 _**Total cash funds**_ **20,410 -** (agree balances with receipts and payments account(s)) **OK OK Unrestricted Restricted funds funds to nearest £ to nearest £** 

## **Fund to which** 

**asset belongs Cost (optional)** 



## **Fund to which** 

**asset belongs Cost (optional)** 

|**Fund to which**<br>**Amount due**<br>**liability relates**<br>**(optional)**|**Fund to which**<br>**Amount due**<br>**liability relates**<br>**(optional)**|**Fund to which**<br>**Amount due**<br>**liability relates**<br>**(optional)**|
|---|---|---|
||||
||||
||||
||||
||||
||||
|ature<br>Print Name|||
||E MARSHALL||
||||



2 



###
CHARnY COMMISSION
Recel
For thg poriQ
Sectlon A Recelpts and payments
Al Roc
rants
AHJ
un
r•c•i
265
'4PheJsrt9 f X
695
ReP&Yrne￿t for luTrJ¥ recelved
J4,119
A4 A6s•1 and In¥•￿m•
AS 1
A6 Ca¥h
C•sh lunds thi¥ •rnl
Section B Statefnent of a55et5 and l i

-15,319 

0 

**OK** 

**Endowment funds to nearest £** 


**----- Start of picture text -----**<br>
-<br>**----- End of picture text -----**<br>



## **Endowment** 

**funds** 

**to nearest £** 

## **Current value** 

**(optional)** 



## **Current value** 

## **(optional)** 

## **When due** 

**(optional)** 

Date of approval 9/18/2026 

9/18/2026 



Soci*l
IJKAOS
monts accounls
I tsand
CC10a
01-J￿-2￿
31 tJ*¢ 74
funds
Total
.oo•
fi.QDU
265
90D
)4.119
10.420
Y.119
bililies at the end of Ihe perlod
fuivJ•
I￿5￿ fvnaT5
4.755
Vnwèstskted
turMI*
Re*trl<ie

Fwnd
Pnnt Trlame
E laARSHALL
24110.202J
¥Jtlf43025

**2025 Incom** 

## **Income and Expenditure Account UK Acute Oncol** 

## _**Income from Donations**_ 

|**_Income from Donations_**||
|---|---|
|Date|Category|
|1/28/2025|Income|
|4/24/2025|Income|
|8/1/2025|Income|
|12/19/2025|Income|
|12/22/2025|Income|
|**Total Result**||



## _**Expenditure from Donations**_ 

|**_Expenditure from Donations_**|**_Expenditure from Donations_**||
|---|---|---|
|cleaned narrative||Date|
|Outward Faster Payment – Media 1productions||12/16/2025|
|Account to Account Transfer – SAWIN & EDWARDS LLP||11/6/2025|
|Outward Faster Payment – Frank Design Ltd||11/6/2025|
|Online Banking Monthly Fee||1/31/2025|
|||2/28/2025|
|||3/28/2025|
|||4/28/2025|
|||5/28/2025|
|||6/27/2025|
|||7/28/2025|
|||8/28/2025|
|||9/26/2025|
|||10/28/2025|
|||11/28/2025|
|||12/24/2025|
|**Total Result**|||





## **me and Expenditure Account** 

## **ogy Society (UKAOS)** 

|cleaned narrative|Sum of Mone|
|---|---|
|Inward Payment – GILEAD SCIENCES LTD(ref: 012/11.12.2024)|4000|
|BACS Payment Received – DAIICHI(0150000359)|4000|
|Inward Payment – CAREOLOGY HEALTH LIMITED|500|
|BACS Payment Received – BIOMERIEUX UK LTD(00072000318198)|12500|
|BACS Payment Received – ASTRAZENECA UK LIM(INV/106625779)|4000|
||**25000**|



|Category|Sum of Mone|
|---|---|
|Secretariate|6708|
|Audit Costs|1473|
|WebSite|924|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
|Bank Fees|20|
||**9345**|





||**Opening Bank Balance (1/1/25)**|**4755.4**|
|---|---|---|
||Income|25000|
|ey In (£)|Expenditure|9345|
||**Closing Bank Balance**|**20410.4**|




ey Out (£) 




Account5tu*•m•nt
ETRO
BANK
J1 JAN2D2
£4 Y554ts SortC4
rdb

## **Source: Ban** 

## Date 

1/31/2025 2/28/2025 3/28/2025 4/28/2025 5/28/2025 6/27/2025 7/28/2025 8/28/2025 9/26/2025 10/28/2025 11/28/2025 12/24/2025 1/28/2025 4/24/2025 8/1/2025 12/19/2025 12/22/2025 11/6/2025 11/6/2025 12/16/2025 



## **nak Statements** 

Description Online Banking Monthly Fee [eu-prod.as...rosoft.com] Online Banking Monthly Fee [eu-prod.as...rosoft.com] Online Banking Monthly Fee [statement-...25-January | PDF] Online Banking Monthly Fee [statement-...5-February | PDF] Online Banking Monthly Fee [statement-2025-March | PDF] Online Banking Monthly Fee [statement-2025-April | PDF] Online Banking Monthly Fee [statement-2025-May | PDF] Online Banking Monthly Fee [statement-2025-June | PDF] Online Banking Monthly Fee [statement-2025-July | PDF] Online Banking Monthly Fee [statement-...025-August | PDF] Online Banking Monthly Fee [statement-...-September | PDF] Online Banking Monthly Fee [statement-...25-October | PDF] Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024) [eu-prod.as...rosoft.com] BACS Payment Received – DAIICHI (0150000359) [statement-...5-February | PDF] Inward Payment – CAREOLOGY HEALTH LIMITED [statement-2025-June | PDF] BACS Payment Received – BIOMERIEUX UK LTD (00072000318198) [statement-...25-October | PDF] BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779) [statement-...25-October | PDF] Account to Account Transfer – SAWIN & EDWARDS LLP (UKAOS) [statement-...-September | PDF] Outward Faster Payment – Frank Design Ltd [statement-...-September | PDF] Outward Faster Payment – Media 1 productions [statement-...25-October | PDF] 



|Money In (£)|Money Out (£)|Balance After (£)|Category|
|---|---|---|---|
|0|20|8735.4|Bank Fees|
|0|20|8715.4|Bank Fees|
|0|20|8695.4|Bank Fees|
|0|20|12675.4|Bank Fees|
|0|20|12655.4|Bank Fees|
|0|20|12635.4|Bank Fees|
|0|20|12615.4|Bank Fees|
|0|20|13095.4|Bank Fees|
|0|20|13075.4|Bank Fees|
|0|20|13055.4|Bank Fees|
|0|20|10638.4|Bank Fees|
|0|20|20410.4|Bank Fees|
|4000|0|8755.4|Income|
|4000|0|12695.4|Income|
|500|0|13115.4|Income|
|12500|0|16430.4|Income|
|4000|0|20430.4|Income|
|0|1473|10658.4|Audit Costs|
|0|924|12131.4|WebSite|
|0|6708|3930.4|Secretariate|





cleaned narrative Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Online Banking Monthly Fee Inward Payment – GILEAD SCIENCES LTD (ref: 012/11.12.2024) BACS Payment Received – DAIICHI (0150000359) Inward Payment – CAREOLOGY HEALTH LIMITED BACS Payment Received – BIOMERIEUX UK LTD (00072000318198) BACS Payment Received – ASTRAZENECA UK LIM (INV/106625779) Account to Account Transfer – SAWIN & EDWARDS LLP (UKAOS) Outward Faster Payment – Frank Design Ltd Outward Faster Payment – Media 1 productions 

